CETP inhibition in cardiovascular risk management: A critical appraisal

European Journal of Clinical Investigation

Volumn 37, Issue 2, 2007, Pages 90-98

  Dullaart, R P F ^a   Dallinga Thie, G M ^b   Wolffenbuttel, B H R ^a   Van Tol, A ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Cholesteryl ester transfer protein; Cholesteryl ester transfer protein inhibitors; Genetics; High density lipoprotein cholesterol; Triglycerides

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTISENSE OLIGODEOXYNUCLEOTIDE; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD EXAMINATION; CARDIOVASCULAR RISK; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEMATOLOGY; HUMAN; HYPERTRIGLYCERIDEMIA; IC 50; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RABBIT; REVIEW; SIDE EFFECT; VITAL SIGN;

ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERTRIGLYCERIDEMIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 33846033977     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01756.x     Document Type: Review

References (71)

1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
2. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9.
3. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-9.
4. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-28.
5. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-81.
6. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, Von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16.
7. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005;4:193-205.
8. Dullaart RPF, Groener JEM, Erkelens DW. Cholesteryl ester transfer between lipoproteins. Diab Nutr Metab 1991;14:329-43.
9. Tall AR. Plasma Cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74.
10. Borggreve SE, De Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69.
11. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991;88:2059-66.
12. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BHR, van Tol A et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;54:3554-9.
13. Guerin M, Le Goff W, Lassel TS, van Tol A, Steiner G, Chapman MJ. Proatherogenic role of elevated cholesteryl ester transfer from HDL to VLDL1 and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001;21:282-8.
14. Colhoun HM, Scheek LM, Rubens MB, van Gent T, Underwood SR, Fuller JH et al. Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 2001;50:652-9.
15. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.
16. Lagrost L, Gambert P, Lallemant C. Combined effects of lipid transfers and lipolysis on gradient gel patterns of human plasma LDL. Arterioscler Thromb 1994;14:1327-36.
17. Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol 1999;10:321-7.
18. Gautier T, Masson D, Jong MC, Pais De Barros JP, Duverneuil L, Le GN et al. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. Biochem J 2005;385:189-95.
19. Fielding CJ, Havel RJ. Cholesteryl ester transfer protein: friend or foe? J Clin Invest 1996;97:2687-8.
20. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004;45:1594-607.
21. Stein O, Stein Y. Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 2005;178:217-30.
22. Thompson GR. Is good cholesterol always good? BMJ 2004;329:471-2.
23. Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol 2004;24:1755-60.
24. Yancey PG, Bortnick AE, Kellner-Weibel G, De la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712-9.
25. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002;13:135-9.
26. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999;145:227-38.
27. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1 - but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 2004;279:9930-6.
28. Matsuura F, Wang N, Chen W, Jiang XC, Tall AR. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 2006;116:1435-42.
29. Zhang Z, Yamashita S, Hirano K, Nakagawa-Toyama Y, Matsuyama A, Nishida M et al. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis 2001;159:67-75.
30. Gauthier A, Lau P, Zha X, Milne R, McPherson R. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005;25:2177-84.
31. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA et al. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 1991;266:10796-801.
32. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73-5.
33. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in apoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 1999;19:1105-10.
34. Herrera VL, Makrides SC, Xie HX, Adari H, Krauss RM, Ryan US et al. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med 1999;5:1383-9.
35. Herrera VLM, Tsikoudakis A, Didishvili T, Ponce LR, Bagamasbad P, Gantz D et al. Analysis of gender-specific atherosclerosis susceptibility in transgenic[hCETP]25DS rat model. Atherosclerosis 2004;177:9-18.
36. Hayek T, Masucci ML, Jiang X, Walsh A, Rubin E, Breslow JL et al. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest 1995;96:2071-4.
37. MacLean PS, Bower JF, Vadlamudi S, Osborne JN, Bradfield JF, Burden HW et al. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice. Arterioscler Thromb Vasc Biol 2003;23:1412-5.
38. Cazita PM, Berti JA, Aoki C, Gidlund M, Harada LM, Nunes VS et al. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res 2003;44:33-40.
39. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 1997;17:1053-9.
40. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-7.
41. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 2003;44:1080-93.
42. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Bakker SJ, van der Steege G et al. The effect of CETP -629C>A promoter polymorphism on HDL cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab 2005;90:4198-202.
43. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13 677 subjects. Circulation 2005;111:278-87.
44. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Zuurman MW, van der SG et al. An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 2006;91:3382-8.
45. Foger B, Luef G, Ritsch A, Schmidauer C, Doblinger A, Lechleitner M et al. Relationship of high-density lipoprotein subfractions and cholesteryl ester transfer protein in plasma to carotid artery wall thickness. J Mol Med 1995;73:369-72.
46. de Grooth GJ, Van Smilde TJWS, Klerkx AH, Zwinderman AH, Fruchart JC, Fruchart JC et al. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis 2004;173:261-7.
47. Klerkx AH, de Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest 2004;34:21-8.
48. Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition) -Norfolk population study. Circulation 2004;110:1418-23.
49. Borggreve SE, Hillige JL, Dallinga-Thie GM, de Jong PE, Wolffenbuttel BHR, Grobbee DE et al. High plasma cholesteryl ester transfer protein may favour reduced incidence of cardiovascular events in men with low triglycerides, submitted.
50. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998;273:5033-6.
51. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2106-12.
52. Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, Jingjing L. Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci 2005;77:2690-702.
53. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7.
54. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 2002;103:587-94.
55. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004;24:490-7.
56. Maeda K, Okamoto H, Shinkai H. S-(2-(acylamino) phenyl) 2,2-dimethylpropanethioates as CETP inhibitors. Bioorg Med Chem Lett 2004;14:2589-91.
57. Bruckner D, Hafner FT, Li V, Schmeck C, Telser J, Vakalopoulos A et al. Dibenzodioxocinones - a new class of CETP inhibitors. Bioorg Med Chem Lett 2005;15:3611-4.
58. Hope HR, Heuvelman D, Duffin K, Smith C, Zablocki J, Schilling R et al. Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: involvement of a critical cysteine. J Lipid Res 2000;41:1604-14.
59. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006;47:537-52.
60. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65.
61. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
62. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 2005;3:789-820.
63. Kuivenhoven JA, de Grooth GJ, Kawamura H, Klerkx AH, Wilhelm F, Trip MD et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8.
64. Kobayashi J, Okamoto H, Otabe M, Bujo H, Saito Y. Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis 2002;162:131-5.
65. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005;25:1057-64.
66. Kee P, Caiazza D, Rye KA, Barrett PH, Morehouse LA, Barter PJ. Effect of inhibiting cholesteryl ester transfer protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma: in vivo studies in rabbits. Arterioscler Thromb Vasc Biol 2006;26:884-90.
67. Zhang B, Fan P, Shimoji E, Xu H, Takeuchi K, Bian C et al. Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol 2004;24:1910-5.
68. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003;169:113-20.
69. Davidson MH, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average highdensity cholesterol levels. J Am Coll Cardiol 2006;48:1774-81.
70. McKenney JM, Davidson MH, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006;48:1782-90.
71. Berelowitz M. Letter to Pfizer consultants. Pfizer Inc., New York, USA, 2 December 2006.